-
Raymond James Starts Lexeo Therapeutics (LXEO) at Strong Buy, PT $25
-
Lexeo Therapeutics' (LXEO) PKP2-ACM Program Under the Radar - Cantor Fitzgerald
-
Oppenheimer Reiterates Outperform Rating on Lexeo Therapeutics (LXEO)
-
Lexeo Therapeutics (LXEO) PKP2-ACM Data Can Put Stock on Radars - Cantor Fitzgerald
-
Cantor Fitzgerald Starts Lexeo Therapeutics (LXEO) at Overweight
-
Lexeo Therapeutics, Inc. (LXEO) Tops Q3 EPS by 51c
-
Lexeo Therapeutics (LXEO) files for 1.25M share offering by selling stockholders
-
Lexeo Therapeutics (LXEO) PT Lowered to $13 at H.C. Wainwright
-
Lexeo Therapeutics (LXEO) PT Lowered to $18 at Stifel
-
Lexeo Therapeutics (LXEO) PT Raised to $15 at H.C. Wainwright
-
Lexeo advances toward accelerated approval for gene therapy
-
Lexeo Therapeutics (LXEO) PT Lowered to $9 at H.C. Wainwright
-
Lexeo Therapeutics, Inc. (LXEO) Tops Q2 EPS by 31c
-
Lexeo Therapeutics (LXEO) PT Lowered to $9 at Leerink Partners
-
Oppenheimer Starts Lexeo Therapeutics (LXEO) at Outperform
-
Stifel Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
-
Lexeo gets FDA breakthrough therapy designation for heart condition drug
-
Lexeo Therapeutics (LXEO) Files for 41.63M Share Offering by Selling Stockholders
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
Lexeo Therapeutics (LXEO) PT Lowered to $10 at Leerink Partners
-
Lexeo Therapeutics (LXEO) Announces $80M Equity Financing
-
Lexeo Therapeutics (LXEO) PT Lowered to $15 at H.C. Wainwright
-
Lexeo Therapeutics, Inc. (LXEO) Misses Q1 EPS by 10c
-
Lexeo Therapeutics, Inc. (LXEO) Misses Q1 EPS by 10c
-
H.C. Wainwright Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
-
Lexeo Therapeutics (LXEO) Announces Positive Interim Phase 1/2 Data for LX2006
-
H.C. Wainwright Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
-
Lexeo Therapeutics (LXEO) PT Lowered to $18 at Leerink Partners, 'we continue to see favorable risk/reward into 2H25'
-
Lexeo Therapeutics, Inc. (LXEO) Misses Q4 EPS by 6c
-
Lexeo Therapeutics (LXEO) Appoints Kyle Rasbach as CFO
-
Lexeo Therapeutics (LXEO) Files $300M Mixed Shelf
-
Lexeo Therapeutics (LXEO) PT Raised to $23 at H.C. Wainwright
-
Lexeo Therapeutics, Inc. (LXEO) Misses Q3 EPS by 17c
-
Lexeo Therapeutics (LXEO) Reports Positive Interim Data for LX1001
-
Stifel Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
-
Lexeo Therapeutics (LXEO) PT Lowered to $21 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
-
Stifel on Lexeo Therapeutics (LXEO): 'FA-CM Data Look Promising Though Handful of Questions for 8AM Call'
-
Lexeo Therapeutics (LXEO) Reports Positive Interim Phase 1/2 Clinical Data of LX2006
-
Baird Starts Lexeo Therapeutics (LXEO) at Outperform

